including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
PET/MRI rules out tau protein in late-life depression Will Morton
Tau PET identifies grey matter atrophy in retired athletes
Study explores neurologic problems in Pluvicto patients
NORTHSTAR MEDICAL RADIOISOTOPES SPONSORS STUDY ENTITLED “PROGRAM TO FIND A CURE FOR ANCA-ASSOCIATED VASCULITIS THROUGH RESEARCH”
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
Blue Earth Diagnostics, a Bracco Company, Announces Results Evaluating Diagnostic Performance of POSLUMA® (Flotufolastat F 18) and Clinical Trial Enrollment in African American Men with Prostate Cancer
